SOUTH SAN FRANCISCO, Calif., Nov. 19 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced that Jerry McMahon, Ph.D., chairman and CEO, will present at the Lazard Capital Markets Fourth Annual Healthcare Conference on Tuesday, November 27, at 9:30 a.m. Eastern Time at The New York Palace Hotel.
Dr. McMahon will provide a corporate overview, including a discussion of the clinical development program for picoplatin, the Company’s lead product candidate.
A live audio webcast of the presentation will be available for 10 business days on the “Events” page of the “News & Events” section of the Company’s website at http://www.poniard.com.
About Poniard Pharmaceuticals
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company’s lead platform product candidate, is a new generation platinum therapy with an improved safety profile. Picoplatin is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and two Phase 2 trials, in metastatic colorectal and hormone-refractory prostate cancers, as well as a Phase 1 clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.
(C) 2007 Poniard Pharmaceuticals, Inc. All Rights Reserved. Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.
CONTACT: Brendan Doherty, Corporate Communications of Poniard
Pharmaceuticals, +1-650-745-4425, bdoherty@poniard.com
Web site: http://www.poniard.com/
